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Retrospective study of CMV retinitis in patients with AIDS
M. Pauriah and E. L. C. Ong
Department of Infection & Tropical Medicine, Newcastle University Medical School, Newcastle General Hospital, Newcastle-
upon-Tyne NE4 6BE, UK
Objective To study the characteristics of clinical presentations and treatment outcome of patients with HIV
infection who developed cytomegalovirus(CMV) retinitis.
Methods A retrospective study for the period 1986–97 at the regional Unit of Infectious Diseases, Newcastle
General Hospital; a teaching hospital in the north-east of England. Twenty-seven patients with advanced HIV
disease and clinically confirmed CMV retinitis were studied. The mean age was 40.8 years, standard deviation
26.3 years. The male : female ratio was 25 : 2. Twenty-six of the patients were white Caucasians and one was
of Afro-Caribbean origin.
Results The median time between the first AIDS-defining diagnosis and development of CMV retinitis was
1.5 years and the CD4+ cell count at the time of diagnosis of CMV retinitis was 7/mm3. After 14 months of
treatment. 80% of patients on mono antiretroviral therapy had impairment of sight (visual acuity 3/60) versus
30% for those on triple antiretroviral therapy. In the same period, the survival rate was 18 versus 70% for mono
versus triple antiretroviral therapy, respectively.
Conclusion The outcome for patients with CMV retinitis was significantly better for those who were on
triple than for those on mono antiretroviral therapy.
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INTRODUCTION
Cytomegalovirus (CMV) is a human herpes virus that con-
tributes to morbidity and mortality among individuals with
HIV infection. Overt CMV infection develops in 20% of HIV-
infected individuals within 2 years once the CD4+ counts have
fallen below 100/mm3 [1]. Among homosexual individuals
with AIDS, the rate of CMV seropositivity approaches 100%
[2]. In autopsy studies, up to 90% of individuals with AIDS
have histological evidence of CMV infection. CMV retinitis
develops in 25 to 40% of individuals with AIDS and, if untreated
causes progressive visual loss [3]. Although chorioretinitis is the
most common presentation, CMV can also cause esophagitis,
colitis, pneumonia and central nervous system disease.
The Department of Infection and Tropical Medicine in
Newcastle-upon-Tyne is the tertiary referral centre for the
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care and treatment of individuals with HIV infection in the
Northern region and in 1999 had 180 individuals under active
follow-up. Patients with CMV retinitis were treated with
intravenous ganciclovir as first choice and foscarnet as second
choice. Induction therapy was administered for 2–3 weeks or
until the retinitis stabilized. Ganciclovir 5 mg/kg twice a day
or foscarnet 90 mg/kg were administered through an indwelling
Nutricath (Vygon, Ecouen, France) catheter inserted sub-
cutanously via the subclavian vein. Surgical placement of an
intravitreal ganciclovir implant was introduced into clinical
practice in 1997.
A retrospective study was undertaken to investigate the
characteristics of clinical presentation and treatment outcome
in individuals with HIV infection who subsequently developed
CMV retinitis and to assess whether there had been any change
in survival since the introduction of highly active antiretroviral
therapy (HAART).
METHODS
Twenty-seven patients with AIDS and confirmed CMV reti-
nitis were identified from the hospital register records. The
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diagnosis of CMV retinitis was made clinically by characteristic
fundoscopic appearances and positive CMV serology and by
subsequent response to ganciclovir or foscarnet therapy. The
hospital notes were examined and the following details
extracted: age, sex, mode of acquisition of HIV infection,
CD4+ count at presentation, antiretroviral therapy, date of
diagnosis of CMV retinitis together with the CD4+ count at
that time, treatment, side-effects of treatment and response.
Information about the HIV viral load was not available in the
majority of cases prior to October 1997.
RESULTS
Of the 27 patients identified as having CMV retinitis, 20 (74%)
had died and seven (26%) were still alive. Twenty-five (93%)
were males; 26 (96%) were white Caucasians and one was an
Afro-Caribbean. Their ages varied between 30 and 67, with
two cases being aged 67 at the time of diagnosis of CMV
retinitis.
Twenty-four (86%) acquired HIV infection through homo-
sexual contact, one through heterosexual contact, another one
through intravenous drug use and the exact route of infection
of the remaining patient was unknown.
The CD4+ count at presentation of their HIV infection
varied from less than 10 up to 530/mm3 with a median of 100
cells/mm3. Twenty (74%) patients had a count 200/mm3.
Ten (37%) were on triple antiretroviral therapy combination,
14 (52%) were on mono antiretroviral therapy and the remain-
ing three (11%) were on dual therapy. Patients treated with
mono antiretroviral therapy were those in the early part of the
study period who had died before the unit started the use of
triple combination and those on dual therapy were those who
could not tolerate the triple combination of drugs. Table 1
shows the details of each individual patient.
Twenty-two (81%) were initially treated with ganciclovir for
retinitis, three (11%) with foscarnet and two had ganciclovir
implants. Of those who were initially treated with ganciclovir,
seven (32%) developed bone marrow suppression; for three
patients (14%) it was severe enough to require a change to
foscarnet. For those on foscarnet, two (66%) had to be changed
to ganciclovir due to renal impairment caused by foscarnet.
AIDS defining diagnosis and onset of CMV retinitis
The interval between the start of an AIDS-defining episode
and the onset of CMV retinitis generally varied between 0 and
4 years, although it was 9 years for one patient as shown in
Figure 1. This is a cumulative frequency curve displaying the
total number of individuals developing CMV retinitis versus
time. The median interval was 1.5 years and by 2.2. years 80%
of the sample had developed this complication.
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CD4+ cell count at the time of diagnosis of CMV retinitis and pro-
gression of the disease
The CD4+ count of patients at the time of diagnosis of CMV
retinitis varied from 10 up to 100/mm3. Figure 2 shows the
cumulative frequency curve of patients and their CD4+ counts.
The median count was 7/mm3 and 90% of patients with the
disease had counts of 51/mm3.
For the 14 patients on mono antiretroviral therapy, no
impairment of sight in the affected eye developed during the
first 5 months of treatment. For the eight who survived this
period, five (63%) had impairment of sight in the affected eye
(visual acuity 3/60) by 12 months. Only two were alive after
2.5 years and neither had evidence of active CMV retinitis.
However, the outcome for those on triple therapy was different
in that only three (30%) had visual acuity reduced to  3/60
by the 14th month, compared with over 80% for those on
mono antiretroviral therapy.
Survival
Figure 3 shows the survival time in months after the diagnosis
of CMV retinitis in patients on mono-antiretroviral therapy;
50% of the individuals who were on monotherapy had died in
the 6 months following the diagnosis of CMV retinitis.
However, the results are quite different for patients on the
triple combination of drugs. After 14 months of treatment, 70%
were still alive compared with 18% on mono antiretroviral
therapy. It should be noted that in fact only three patients on
triple combination had died (one at 3 months, one at 9 months
and the last at 29 months).
DISCUSSION
This retrospective study showed that the median time between
the first AIDS-defining event and developing CMV retinitis
was 1.5 years and the median CD4+ count at the time of
diagnosis was 7 cells/mm3. Eighty per cent of patients on mono
antiretroviral therapy after 14 months had impairment of sight
compared with 30% of those who were being treated with the
triple therapy. The survival rate was 18 versus 70%, respectively.
The introduction of HAART has reduced the incidence of
CMV infection in HIV-positive populations. The addition of
protease inhibitors as part of the HAART has been documented
to show beneficial effects in sustaining CD4+ counts par-
ticularly in the first 16 weeks of treatment. This corresponds
with a prolonged period of inactive CMV retinitis [4] which
we have similarly found in three of our patients in this study.
Immunological reconstitution can occur after prolonged sup-
pression of HIV activity suggesting that, for selected patients
with healed CMV retinitis, temporary discontinuation of
prophylaxis may not result in further retinal necrosis [5–7].
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Figure 1 Cumulative frequency curve showing total number of pat-
ients who developed CMV retinitis versus time.
Figure 2 Cumulative frequency curve of patients and CD4+ counts.
Figure 3 Survival time of patients with CMV retinitis on mono anti-
retroviral therapy.
However, there have been reports of patients developing CMV
retinitis while receiving HAART. CMV-specific T cells may
have been exhausted in such patients and therefore no expan-
sion of T cells to restore such immunity could be expected [8].
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Alternatively, an improved CMV-specific immune response
may have not penetrated the eye and this may explain why
protease inhibitors prevented nonretinal CMV disease but not
CMV retinitis in patients with advanced HIV disease [9].
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